302 related articles for article (PubMed ID: 26850074)
1. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.
Bradford Rice J; White A; Lopez A; Galebach P; Schepman P; Popelar B; Philbin M
J Med Econ; 2016 Jul; 19(7):649-54. PubMed ID: 26850074
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
3. Burden of venous leg ulcers in the United States.
Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
[TBL] [Abstract][Full Text] [Related]
4. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
5. Time-Dependent Analysis of Risk of New-Onset Heart Failure Among Patients With Polymyositis and Dermatomyositis.
Lin CY; Chen HA; Hsu TC; Wu CH; Su YJ; Hsu CY
Arthritis Rheumatol; 2022 Jan; 74(1):140-149. PubMed ID: 34180158
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study.
Chung WS; Lin CL; Sung FC; Lu CC; Kao CH
Thromb Res; 2014 Sep; 134(3):622-6. PubMed ID: 25034321
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
[TBL] [Abstract][Full Text] [Related]
8. Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study.
Miyazaki C; Ishii Y; Stelmaszuk NM
Clin Rheumatol; 2022 Mar; 41(3):741-755. PubMed ID: 34677707
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.
Wang SX; Ganguli AX; Bodhani A; Medema JK; Reichmann WM; Macaulay D
J Med Econ; 2017 Dec; 20(12):1299-1306. PubMed ID: 28880733
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
13. Inpatient burden and resource utilization of polymyositis and dermatomyositis: A 10-year Study of National Inpatient Sample.
Ungprasert P; Wannarong T; Cheungpasitporn W; Wijarnpreecha K; Thongprayoon C; Kroner PT
Joint Bone Spine; 2020 Jul; 87(4):327-330. PubMed ID: 32184181
[TBL] [Abstract][Full Text] [Related]
14. The direct and indirect costs among U.S. privately insured employees with hypogonadism.
Kaltenboeck A; Foster S; Ivanova J; Diener M; Bergman R; Birnbaum H; Kinchen K; Swindle R
J Sex Med; 2012 Sep; 9(9):2438-47. PubMed ID: 22738380
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use.
Christopher-Stine L; Wan GJ; Kelly W; McGowan M; Bostic R; Reed ML
J Manag Care Spec Pharm; 2020 Nov; 26(11):1424-1433. PubMed ID: 33119444
[No Abstract] [Full Text] [Related]
16. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
17. Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score.
Lee CW; Muo CH; Liang JA; Sung FC; Hsu CY; Kao CH
Endocrine; 2016 Apr; 52(1):86-92. PubMed ID: 26429781
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis.
Murray SG; Schmajuk G; Trupin L; Lawson E; Cascino M; Barton J; Margaretten M; Katz PP; Yelin EH; Yazdany J
Arthritis Care Res (Hoboken); 2015 May; 67(5):673-80. PubMed ID: 25331828
[TBL] [Abstract][Full Text] [Related]
19. Burden of diabetic foot ulcers for medicare and private insurers.
Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons NB
Diabetes Care; 2014; 37(3):651-8. PubMed ID: 24186882
[TBL] [Abstract][Full Text] [Related]
20. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
